<?xml version="1.0" encoding="UTF-8"?>
<p>Currently, MERS‐CoV is still a relevant threat for populations in the Middle East, with a high lethality (close to 35%) [
 <xref rid="ene14277-bib-0002" ref-type="ref">2</xref>]. Patients exhibit predominantly pulmonary clinical involvement in contrast to fewer patients presenting neurological manifestations such as coma, ataxia, focal motor deficits and peripheral nerve symptoms [
 <xref rid="ene14277-bib-0024" ref-type="ref">24</xref>, 
 <xref rid="ene14277-bib-0025" ref-type="ref">25</xref>]. Unfortunately, there are no published data regarding human neuropathological findings (Table 
 <xref rid="ene14277-tbl-0001" ref-type="table">1</xref>).
</p>
